[1] Ling H. Clinical approach to progressive supranuclear palsy [J]. J Mov Disord, 2016, 9(1): 3-13. [2] Kaat DL, Chiu WZ, Boon AJ, et al. Recent advances in progressive supranuclear palsy: a review [J]. Curr Alzheimer Res, 2011, 8(3): 295-302. [3] Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop [J]. Neurology, 1996, 47(1): 1-9. [4] 中华医学会神经病学分会帕金森病及运动障碍学组,中国医师协会神经内科医师分会帕金森病及运动障碍专业委员会. 中国进行性核上性麻痹临床诊断标准[J]. 中华神经科杂志, 2016, 49(4): 272-276. [5] Nath U, Thomson R, Wood R, et al. Population based mortality and quality of death certification in progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) [J]. J Neurol Neurosurg Psychiatry, 2005, 76(4): 498-502. [6] Ling H, Massey LA, Lees AJ, et al. Hypokinesia without decrement distinguishes progressive supranuclear palsy from Parkinson's disease [J]. Brain, 2012, 135(Pt 4): 1141-1153. [7] Respondek G, Stamelou M, Kurz C, et al. The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases [J]. Mov Disord, 2014, 29(14): 1758-1766. [8] Facheris MF, Maniak S, Scaravilli F, et al. Pure akinesia as initial presentation of PSP: a clinicopathological study [J]. Parkinsonism Relat Disord, 2008, 14(6): 517-519. [9] Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration [J]. Neurology, 2013, 80(5): 496-503. [10] Josephs KA, Duffy JR. Apraxia of speech and nonfluent aphasia: a new clinical marker for corticobasal degeneration and progressive supranuclear palsy [J]. Curr Opin Neurol, 2008, 21(6): 688-692. [11] Hassan A, Parisi JE, Josephs KA. Autopsy-proven progressive supranuclear palsy presenting as behavioral variant frontotemporal dementia [J]. Neurocase, 2012, 18(6): 478-488. [12] Kanazawa M, Tada M, Onodera O, et al. Early clinical features of patients with progressive supranuclear palsy with predominant cerebellar ataxia [J]. Parkinsonism Relat Disord, 2013, 19(12): 1149-1151. [13] Liscic RM, Srulijes K, Gröger A, et al. Differentiation of progressive supranuclear palsy: clinical, imaging and laboratory tools [J]. Acta Neurol Scand, 2013, 127(5): 362-370. [14] Quattrone A, Nicoletti G, Messina D, et al. MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy [J]. Radiology, 2008, 246(1): 214-221. [15] 朱银伟,孙永安,陈俊,等. 磁共振帕金森指数对进行性核上性麻痹的诊治提示[J]. 中国神经精神疾病杂志, 2012, 38(9):547-550. [16] Wang G, Wang J, Zhan J, et al. Quantitative assessment of cerebral gray matter density change in progressive supranuclear palsy using voxel based morphometry analysis and cerebral MR T1-weighted FLAIR imaging [J]. J Neurol Sci, 2015, 359(1-2): 367-372. [17] Golbe LI, Ohman-Strickland PA. A clinical rating scale for progressive supranuclear palsy [J]. Brain, 2007, 130(Pt 6): 1552-1565. [18] Hall DA, Forjaz MJ, Golbe LI, et al. Scales to assess clinical features of progressive supranuclear palsy: MDS task force report [J]. Mov Disord Clin Pract, 2015, 2(2): 127-134. [19] Ghosh BC, Carpenter RH, Rowe JB. A longitudinal study of motor, oculomotor and cognitive function in progressive supranuclear palsy [J]. PLoS One, 2013, 8(9): e74486. [20] Liepelt I, Gaenslen A, Godau J, et al. Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: Clinical observations as a basis for power calculations and safety analysis [J]. Alzheimers Dement, 2010, 6(1): 70-74. [21] Stamelou M, de Silva R, Arias-Carrión O, et al. Rational therapeutic approaches to progressive supranuclear palsy [J]. Brain, 2010, 133(Pt 6): 1578-1590. [22] Lamb R, Rohrer JD, Lees AJ, et al. Progressive supranuclear palsy and corticobasal degeneration: pathophysiology and treatment options [J]. Curr Treat Options Neurol, 2016, 18(9): 42. [23] Daniele A, Moro E, Bentivoglio AR. Zolpidem in progressive supranuclear palsy [J]. N Engl J Med, 1999, 341(7): 543-544. [24] Chang AY, Weirich E. Trial of zolpidem, eszopiclone, and other GABA agonists in a patient with progressive supranuclear palsy [J]. Case Rep Med, 2014, 2014: 107064. [25] Litvan I, Phipps M, Pharr VL, et al. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy [J]. Neurology, 2001, 57(3): 467-473. [26] Boxer AL, Lang AE, Grossman M, et al. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial [J]. Lancet Neurol, 2014, 13(7): 676-685. [27] Tolosa E, Litvan I, Höglinger GU, et al. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy [J]. Mov Disord, 2014, 29(4): 470-478. [28] Apetauerova D, Scala SA, Hamill RW, et al. CoQ10 in progressive supranuclear palsy: A randomized, placebo-controlled, double-blind trial [J]. Neurol Neuroimmunol Neuroinflamm, 2016, 3(5): e266. [29] Nuebling G, Hensler M, Paul S, et al. PROSPERA: a randomized, controlled trial evaluating rasagiline in progressive supranuclear palsy [J]. J Neurol, 2016, 263(8): 1565-1574. [30] Choi SW, Park KB, Woo SK, et al. Treatment of progressive supranuclear palsy with autologous adipose tissue-derived mesenchymal stem cells: a case report [J]. J Med Case Rep, 2014, 8: 87. [31] Giordano R, Canesi M, Isalberti M, et al. Autologous mesenchymal stem cell therapy for progressive supranuclear palsy: translation into a phase I controlled, randomized clinical study [J]. J Transl Med, 2014, 12: 14. [32] Servello D, Zekaj E, Saleh C, et al. Long-term follow-up of deep brain stimulation of peduncolopontine nucleus in progressive supranuclear palsy: report of three cases [J]. Surg Neurol Int, 2014, 5(Suppl 8): S416-S420. [33] Izzo KL, DiLorenzo P, Roth A. Rehabilitation in progressive supranuclear palsy: case report [J]. Arch Phys Med Rehabil, 1986, 67(7): 473-476. [34] Zampieri C, Di FRP. Balance and eye movement training to improve gait in people with progressive supranuclear palsy: quasi-randomized clinical trial [J]. Phys Ther, 2008, 88(12): 1460-1473. [35] Sale P, Castiglioni D, De Pandis MF, et al. The Lee Silverman Voice Treatment (LSVT ® ) speech therapy in progressive supranuclear palsy [J]. Eur J Phys Rehabil Med, 2015, 51(5): 569-574. [36] Sale P, Stocchi F, Galafate D, et al. Effects of robot assisted gait training in progressive supranuclear palsy (PSP): a preliminary report [J]. Front Hum Neurosci, 2014, 8: 207. [37] Suteerawattananon M, MacNeill B, Protas EJ. Supported treadmill training for gait and balance in a patient with progressive supranuclear palsy [J]. Phys Ther, 2002, 82(5): 485-495. [38] Steffen TM, Boeve BF, Petersen CM, et al. Long-term exercise training for an individual with mixed corticobasal degeneration and progressive supranuclear palsy features: 10-year case report follow-up [J]. Phys Ther, 2014, 94(2): 289-296. [39] Seamon B, DeFranco M, Thigpen M. Use of the Xbox Kinect virtual gaming system to improve gait, postural control and cognitive awareness in an individual with progressive supranuclear palsy [J]. Disabil Rehabil, 2017, 39(7): 721-726. [40] Hanson WR, Metter EJ. DAF as instrumental treatment for dysarthria in progressive supranuclear palsy: a case report [J]. J Speech Hear Disord, 1980, 45(2): 268-276. [41] Boulogne S, Le CF, Bation R, et al. Repetitive transcranial magnetic stimulation can alleviate treatment-resistant depression in patients with progressive supranuclear palsy [J]. Parkinsonism Relat Disord, 2015, 21(9): 1113-1114. [42] Dunlop SR, Kent VP, Lashley M, et al. The cure PSP care guide: a telephonic nursing intervention for individuals and families living with progressive supranuclear palsy [J]. J Neurosci Nurs, 2016, 48(2): 105-106. [43] Golbe LI, Davis PH, Schoenberg BS, et al. Prevalence and natural history of progressive supranuclear palsy [J]. Neurology, 1988, 38(7): 1031-1034. [44] Oropesa-Ruiz JM, Huertas-Fernández I, Jesús S, et al. Low serum uric acid levels in progressive supranuclear palsy [J]. Mov Disord, 2016, 31(3): 402-405. [45] Tomita S, Oeda T, Umemura A, et al. Impact of aspiration pneumonia on the clinical course of progressive supranuclear palsy: a retrospective cohort study [J]. PLoS One, 2015, 10(8): e0135823. [46] Nozaki I, Kato-Motozaki Y, Ikeda T, et al. Aspiration pneumonia and bronchopneumonia in progressive supranuclear palsy treated with Qing Fei Tang: two case reports [J]. J Med Case Rep, 2015, 9: 67. |